How Artificial Intelligence Can Power Clinical Development
McKinsey & Company, Wednesday, November 22,2023
Artificial intelligence is accelerating drug discovery. If clinical development fails to keep pace, the benefits to patients will be delayed.
Clinical development and the randomized clinical trial (RCT) remain largely unaffected by the unprecedented wave of innovation in pharmaceutical R&D fueled by developments in artificial intelligence (AI), including generative AI (gen AI) and foundational models.
However, they are under pressure from the rise of precision medicine and a more competitive development landscape. So far, the adoption of AI for clinical development has emphasized operational excellence and acceleration, but advances in scientific AI have made this the time to leverage modern analytical tools and novel sources of data to design more precise, efficient trials with greater success rates.